Xen Capital
Xen is a pioneering platform that addresses the challenges faced by accredited investors in Asia, who often encounter high barriers to accessing alternative investments such as private equity, venture capital, and real estate. Founded in 2018 by a team of experienced professionals from investment banking and fintech, Xen offers a zero-upfront fee marketplace that promotes transparency and liquidity in alternative asset management. The platform allows for fractionalized access and tradability of investments, enabling a broader range of investors to participate in opportunities typically reserved for ultra-high-net-worth individuals and institutional players. With an AI-driven onboarding process and a user-friendly interface, Xen empowers investors by providing access to institutional-grade investments and enhancing their decision-making autonomy in a traditionally opaque market.
Prenetics Limited is a DNA biotechnology company focused on genetic and diagnostic health testing. It specializes in pharmacogenomics through its iGenes PGx test, which assists physicians in determining the appropriate medication and dosage for patients based on their genetic profiles, also identifying potential adverse drug reactions. Additionally, Prenetics offers ONEdna, a DNA screening service that analyzes individual genes and provides actionable health recommendations. The company operates through its consumer brands, CircleDNA in Asia and DNAFit, empowering individuals with insights into their health risks, dietary needs, and responses to medications using simple saliva samples. Founded in 2007 and based in Central, Hong Kong, Prenetics has established strategic partnerships with organizations such as The Lippo Group and New Horizon Health Limited.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.